



Activity, specificity and disease relevance of N-glycan branching enzymes

**Tokai National Higher Education and Research System
Gifu University
Institute for Glyco-core Research (iGCORE)**


Yasuhiko Kizuka

Background : Protein glycosylation

Glycan and life


Glycan

- covers all cells
- over half of proteins are glycosylated



Glycans are involved in various phenomena and diseases


Glycan functions



Glycan modification

ADCC activity
~100 fold (potelligent)


Erythropoietin (EPO)



Glycan difference
Difference in stability
in blood


**Glycan regulates
protein functions**

Glycans in mammals






([Essentials of Glycobiology 4th ed.](#))

Biosynthetic steps of animal N-glycans



Typical structure of Golgi glycosyltransferase



Much is known about sugar transfer reactions, but the localization mechanism is not understood well

Research question



Biological functions and diseases (cancer, Alzheimer's)

Big question


Glycan patterns are different among proteins

Diverse structures

Glycoprotein



All enzymes were identified




It's unclear how each enzyme works

Goal

Glycosyltransferase (180)

Understanding the mechanisms of protein-dependent glycosylation by glycosyltransferases


Research target: N-glycan branches




How is each branch synthesized in protein-dependent manners?

Topic 1 : GnT-III

N-Glycan



Bisecting GlcNAc and Alzheimer's disease



Alzheimer's Disease (AD)
patients


GnT-III mRNA

Control eAD AD

Upregulated




([Akasaka-Manyu et al. Glycobiology 2010, 20, 99-106](#))

Bisecting GlcNAc and Alzheimer's disease




(Kizuka et al., *EMBO Mol. Med.*, 2015, 7, 175-189)


Bisecting GlcNAc is a key for glycan elongation



Bisecting GlcNAc is a key for glycan elongation




◆ Sialyltransferase ◆ Glucuronyltransferase ▶ Fucosyltransferase




(Nakano et al., *Mol. Cell. Proteomics*, 2019, 18, 2044-2057)

Bisecting GlcNAc suppresses terminal modifications



Terminal structures are increased in GnT-III KO




(Nakano et al., *Mol. Cell. Proteomics*, 2019, 18, 2044-2057)


Question : protein selectivity of GnT-III action

Protein-selective glycosylation

GnT-III WT KO



**Bisecting
GlcNAc**



GnT-III's

1. Amount

➔ mRNA, protein (secretion, degradation)

2. Location


➔ Fine localization in Golgi

3. Reaction

➔ Recognition of polypeptide

Understanding biological functions and diseases

Topic 2 : GnT-IV



GnT-IVa (*MGAT4A*) and type2 diabetes

High expression of
GnT-IVa in pancreas



Insulin secretion
Control of blood glucose

Prof. Ohtsubo
(Kumamoto)

Diabetic phenotype of
GnT-IVa KO mice

Glucose transporter-2 in pancreas
→ enhanced endocytosis



Type2 diabetes

[\(Ohtsubo et al., *Cell*, 2005, 123, 1307-1321\)](#)


[\(Ohtsubo et al., *Nat. Med.*, 2011, 17, 1067-1075\)](#)

Unclear points

Structure and specificity
of GnT-IVa

→ Structural analysis

in collaboration with Dr. Nagae
(Osaka Univ.)



Relatively large as a
glycosyltransferase catalytic domain



multiple domains??





[\(Nagae et al., *Commun. Biol.*, 2022, 5, 695\)](#)

GnT-IVa has a lectin domain


Phyre2 server (prediction of protein fold)

(Kelley et al., *Nat. Protocols*, 2015, 10, 845-858)

C-term region is similar to a bacterial lectin NagH

#	Template	Alignment Coverage	3D Model	Confidence	% i.d.	Template Information
1	c2Is6A_	 Alignment		99.0	14	PDB header: hydrolase Chain: A: PDB Molecule: hyaluronoglucosaminidase; PDBTitle: solution nmr structure of a non-canonical galactose-binding cbm32 from2 clostridium perfringens
2	c5vcmA_	 Alignment		97.7	15	PDB header: transferase Chain: A: PDB Molecule: alpha-1,6-mannosyl-glycoprotein 2-beta-n- PDBTitle: alpha-1,6-mannosyl-glycoprotein 2-beta-n-acetylglucosaminyltransferase2 with bound udp and manganese


N-term region is similar to GnT-II



Binds to GlcNAc

Sugar-binding domain of clostridium glycosidase

NagH CBM32
(PDB code: 2WDB)




Residues conserved between NagH and GnT-IV (red)



GnT-IV C-term is likely a GlcNAc-binding lectin


Crystal structure of the lectin domain

GnT-IVa lectin domain





Crystallization was succeeded

NagH



→ Similar to NagH



Frontal affinity chromatography




Lectin domain recognizes the product glycan

Lectin domain is required for enzyme activity

Glycan binding domain of NagH




Lectin domain is required for full activity




	Km for donor (mM)	Km for acceptor (μ M)
WT	3.24	2444
D445A	3.95	1251

similar **Higher affinity of the mutant (roughly half Vmax)**

Two models




Acceleration of sugar transfer reaction itself



Easy to modify Multiple glycosylation sites in one protein

GnT-IVa, -IVb : Why two isozymes?




Tissue distribution

GnT-IVa
(MGAT4A) Limited tissue
(pancreas, etc)

GnT-IVb
(MGAT4B) Ubiquitous

(Yoshida et al., *Glycoconj. J.*, 1998, 15, 1115-1123)



Both are functional
within the same
cell



Different roles?




Protein selectivity?
(almost the same
specificity toward
glycans)



(Osada et al., *J. Biol. Chem.*, 2022, 298, 102400)

Enzyme activity toward glycoproteins

UDP-Glo assay



Activity toward
6 glycoproteins




**Different protein selectivity
between a and b**

Lectin domain regulates protein selectivity

Structure of lectin domain


Red : conserved between a and b






2 unconserved amino acids

➔ Mutant IVb was purified whose 2 amino acids were replaced by IVa type residues.

UDP-Glo assay



Lectin domain regulates protein selectivity




Lectin domain mutant of GnT-IVb F413H shows IVa-like selectivity



GnT-IVa,b has different protein selectivity regulated by lectin domain

Topic 3 : GnT-V




GnT-V inhibitor is a promising drug candidate against cancer

3D structure of GnT-V (MGAT5)

GnT-V structure

in collaboration
with Dr. Nagae




Substrate analog

Mechanism of glycan recognition

(Nagae[#] and Kizuka[#], *Nat. Commun.*,
2018, 9, 3380)

Structure-based inhibitor design




(Vibhute, et al., *BBA Gen. Subj.*, 2021, 1866,
130118)

Chemistry

Prof. Ando
Dr. Tanaka
(Gifu Univ.)

Recognition of substrate protein




N-domain

Recognition?



(Osuka et al., *J. Biol. Chem.*, 2022, 298, 101666)

ΔN shows reduced activity in cells

GnT-V




HEK293 GnT-V KO





N domain is required for efficient glycosylation in cells

ΔN shows reduced activity in cells

GnT-V



In vitro GnT-V activity




GnT-V ΔN fully retains activity toward glycans


N domain is required for efficient glycosylation in cells

Activity assay toward glycoproteins (UDP-Glo)

UDP-Glo assay




GnT-V activity (UDP-Glo)



N domain is required for activity toward glycoproteins


Regulation of the levels of GnT-V protein



GnT-V is cleaved and secreted

(Hirata, et al., *Commun. Biol.*, 2022, 5, 743)


Small extracellular vesicle (sEV) (exosome etc.)



GnT-V is present in sEV

(Hirata, et al., *iScience*, 2022, 26, 105747)

GnT-V protein is increased by blocking N-glycan maturation




GnT-V is increased by blocking N-glycan maturation

([Hirata, et al., Commun. Biol., 2022, 5, 743](#))

SPPL3-mediated cleavage of GnT-V


Regulation of the GnT-V protein level




Which regulates the level of GnT-V protein dominantly?

SPPL3-mediated shedding dominantly regulates the GnT-V protein level

MG132: proteasome inhibitor
Chloroquine: lysosome inhibitor




Reduced GnT-V shedding by blocking N-glycan maturation



Mechanism of control of GnT-V secretion

Normal state

Immature N-glycan




Amount of GnT-V protein depends on cellular N-glycan maturity

([Hirata, et al., *Commun. Biol.*, 2022, 5, 743](#))

Glycosyltransferase activity in sEV

Hypothesis



Preparation of sEVs

Vesicle size (qNano)

B16

Neuro2A

106 ± 32.6 nm

108 ± 24.3 nm

Exosome markers

B16

Neuro2A

Cell

sEV

(kDa)

Cell

sEV

(kDa)

CD63

CD81

Alix

100
75
50
37

25
20

100

100
75
50
37

25
20







100

Exosome-rich vesicles were prepared

([Hirata, et al., *iScience*, 2022, 26, 105747](#))

Activity of glycosyltransferase in sEVs


N-glycan branching enzymes



GnT-V activity is selectively enriched in sEVs


(Hirata, et al., *iScience*, 2022, 26, 105747)

GnT-V-rich sEVs are incorporated to remodel glycans




GnT-V incorporation

sEVs	-	B16	B16-GnT-V-Halo
CFSE	-	+	+
TMR	-	+	+




GnT-V activity (recipient)

— No enzyme — sEVs (B16)
 — GnT-V — sEVs (GnT-V-Halo)



Glycan change (recipient)


B16
 B16+GnT-V-Halo



GnT-V-sEVs are incorporated to produce glycans

(Hirata, et al., *iScience*, 2022, 26, 105747)

Cell-to-cell transfer of GnT-V mediated by sEV



A possible regulation mechanism of glycan expression without gene expression

Summary

Disease and biological phenomenon

Biological event

- 3D structure
- Specificity




Regulation mechanism

- Localization
- Secretion
- Regulatory factor

Perspective

Protein-selective glycosylation by glycosyltransferase and its medical application



Acknowledgment

Lab member

Tetsuya Hirata

Yuko Tokoro ^{✕Duke Univ.}

Misaki Nakashima

Emiko Mori

Seita Tomida

Reina Osuka

Haruka Kawade

Natsuki Shimizu

Naoko Osada

Yuta Hashimoto

Taichi Nakaishi

Suzune Hayashi

Tomoya Itoh

Aoi Morigo

Osaka Univ.

Masamichi Nagae

Hiroshima Univ.

Miyako Nakano

AIST

Hiroaki Tateno

Univ. Mississippi

Sushil K. Mishra

Robert Doerksen

Gifu Univ. iGCORE

Hiromune Ando

Hidenori Tanaka

Kazuki Nakajima

Kenichi Suzuki

Kyoto Univ.

Shogo Oka

Osaka Int. Cancer Inst.

Naoyuki Taniguchi

Yoichiro Harada

I would like to express my sincere thanks to many other collaborators as well.